<DOC>
	<DOC>NCT00395421</DOC>
	<brief_summary>This study is being conducted to see if the investigational medication, valopicitabine, is safe to use in combination with ribavirin, a drug approved by the FDA for treating hepatitis C infection.</brief_summary>
	<brief_title>Study to Evaluate Drug-drug Interaction Between Valopicitabine and Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Documented clinical history compatible with chronic hepatitis C and compensated liver disease Has not previously received antiviral therapy for hepatitis C infection Other protocoldefined inclusion criteria may apply. Patient is pregnant or breastfeeding Patient is coinfected with hepatitis B virus and/or HIV Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>treatment-naive</keyword>
</DOC>